Amyloid-Journal of Protein Folding Disorders

Papers
(The TQCC of Amyloid-Journal of Protein Folding Disorders is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
A second case of liraglutide-type localised amyloidosis219
Re-evaluation of Mayo 2004 and revised Mayo 2012 staging in patients with AL amyloidosis in the era of new therapies201
A case of asymmetric insulin-derived localised amyloid deposition associated with long-acting insulin analog administration95
Changes in the amyloid editorial board members and in editor positions81
Factors associated with financial toxicity in patients with transthyretin amyloidosis: results from Amyloidosis Research Consortium’s treatment affordability patient and caregiver survey62
Comparison between tafamidis and liver transplantation as first-line therapy for hereditary transthyretin amyloidosis40
Neurofilament light chain as a biomarker for hereditary ATTR amyloidosis − correlation between neurofilament light chain and nerve conduction study34
Real-world treatment patterns, costs, and outcomes in patients with AL amyloidosis: analysis of the Optum EHR and commercial claims databases28
Characterising diflunisal as a transthyretin kinetic stabilizer at relevant concentrations in human plasma using subunit exchange26
Survey of amyloidosis cases among different free-living wild and zoo animals24
Reduction of cardiac AL amyloid deposition after complete response visualised by PiB-PET imaging24
Role of complementarity-determining regions 1 and 3 in pathologic amyloid formation by human immunoglobulin κ1 light chains21
Early cardiovascular autonomic failure in ATTRv predicts poor prognosis and may respond to disease-modifying therapy19
Treatment response measurements and survival outcomes in a cohort of newly diagnosed AL amyloidosis18
Abnormal global longitudinal strain and reduced serum inflammatory markers in cardiac AL amyloidosis patients without significant amyloid fibril deposition17
Factors associated with changes in serum transthyretin after treatment with tafamidis and outcomes in transthyretin cardiac amyloidosis16
Clinical impact of beta-blocker withdrawal in transthyretin amyloid cardiomyopathy16
Human lysozyme inhibits the fibrillation of serum amyloid a protein from systemic AA amyloidosis15
Patients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delay14
Protease resistance of ex vivo amyloid fibrils implies the proteolytic selection of disease-associated fibril morphologies14
A natural history analysis of asymptomatic TTR gene carriers as they develop symptomatic transthyretin amyloidosis in the Transthyretin Amyloidosis Outcomes Survey (THAOS)13
Identification of epidermal growth factor-containing fibulin-like extracellular matrix protein 1-derived amyloid deposition in a rhesus macaque13
Alterations in multi-layer strain in AL amyloidosis13
Management of AL amyloidosis in 2021+12
Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis12
Left atrioventricular coupling index assessed with three-dimensional echocardiography: a prognostic marker of short-term outcomes in light-chain cardiac amyloidosis12
Prevalence and prognostic role of nonsustained ventricular tachycardia in cardiac amyloidosis12
Serum neurofilament light chain in hereditary transthyretin amyloidosis: validation in real-life practice12
Selective recognition of human small transthyretin aggregates by a novel monoclonal antibody11
Natural course and determinants of short-term kidney function decline in hereditary transthyretin amyloidosis: a French observational study10
Clinical and molecular insights into A97S variants in hereditary transthyretin amyloid polyneuropathy in South China10
Utilization and tolerance of beta-blockers among patients with AL amyloidosis10
Mapping cellular response to destabilized transthyretin reveals cell- and amyloidogenic protein-specific signatures9
Whole tissue proteomic analyses of cardiac ATTR and AL unveil mechanisms of tissue damage9
Refining prognostication in systemic AL amyloidosis: limited value of dFLC9
Brain MRI in patients with V30M hereditary transthyretin amyloidosis9
A rare occurrence and near miss! Should a TTR gene test be routinely performed for suspected ATTR-cardiomyopathy?8
Amyloid nomenclature 2024: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee8
Neurological involvement in Ile68Leu (p.Ile88Leu) ATTR amyloidosis: not only a cardiogenic mutation8
Monitoring of cardiac transthyretin amyloid load by [99mTc]DPD scintigraphy: is it the end of the semi-quantitative evaluation?8
Involvement of bile acid in diarrhoea and therapeutic effect of colestimide in hereditary ATTR amyloidosis8
Abnormal electrochemical skin conductance values in patients with AA amyloidosis7
Possible transmission of leukocyte chemotactic factor 2 amyloidosis after interpopulational liver transplantation7
Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines7
Bone marrow amyloid: a comprehensive analysis of 1,469 samples, including amyloid type, clinical features, and morphologic distribution7
Somatostatin-derived amyloidosis: a novel type of amyloidosis associated with well-differentiated somatostatin-producing neuroendocrine tumours7
Longitudinal analysis of serum neurofilament light chain levels as marker for neuronal damage in hereditary transthyretin amyloidosis7
Correction7
Predictors of cognitive dysfunction in hereditary transthyretin amyloidosis with liver transplant7
Epidemiology of hereditary transthyretin amyloidosis in the northernmost region of Sweden: a retrospective cohort study6
Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study6
Complete remission after patisiran treatment in a patient with nephrotic syndrome secondary to hereditary transthyretin amyloidosis (ATTR)6
Incidence and predictors of sudden death in patients with cardiac amyloidosis6
Subtyping of cardiac amyloidosis by mass spectrometry-based proteomics of endomyocardial biopsies6
0.038365840911865